Search

everythinglearnresearchcommunity

for

Search:↓

The user is considering switching from finasteride and minoxidil to dutasteride for better hair regrowth results, as they are experiencing thinning and shedding despite current treatments. They have also tried microneedling, Clobetasol, and salicylic acid to manage scalp issues and inflammation.

The user is experiencing positive results in hair regrowth using a protocol that includes minoxidil, dutasteride, essential growth serum, argan oil, trioxidil shampoo, ketoconazole shampoo, and microneedling. They express hope and satisfaction with the progress after six weeks of treatment.

The user has been using finasteride and dutasteride for six months, experiencing a complete stop in hair shedding but minimal regrowth. They are considering adding RU58841 for potential regrowth, with advice suggesting patience as significant results often take 12-24 months.

A user in their mid-30s experienced unexpected hairline regrowth after starting a new supplement stack, despite being on a regimen of finasteride, minoxidil, and Nizoral for over four years. The new supplements include Tongkat Ali, Fadogia Agrestis, Panax Red Ginseng, Vitamin B1, Vitamin D3, Zinc Picolinate, Magnesium Glycinate, Maca, and L-Citrulline.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

User maintained hair with finasteride for 6 months, then switched to dutasteride for 7 months, using DHT blocking shampoo, keto 2% shampoo, and microneedling. Significant hair growth observed, especially on right temple.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

The user is using a hair regrowth protocol including dutasteride, topical and oral minoxidil, dermarolling, ketoconazole shampoo, and tretinoin, but is experiencing slow progress and seeks advice for faster regrowth. Suggestions include quitting smoking, adjusting the regimen, and considering additional treatments like topical finasteride or RU58841.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

The conversation discusses the potential release date of a hair loss treatment called Pyrilutamide. One user suggests it may be available in about 5 years.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

The user experienced hair loss starting at 16 and used finasteride and minoxidil, later switching to dutasteride and oral minoxidil, which improved hair thickness after an initial shedding phase. The user also noted the importance of using shampoo to manage dermatitis and maintain scalp health.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

The conversation discusses skepticism towards unconventional hair loss remedies, emphasizing the effectiveness of proven treatments like oral DHT blockers, topical minoxidil, and finasteride. It criticizes misleading advice and highlights the importance of starting effective treatments early.

The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

A 20-year-old has been using finasteride and minoxidil for hair loss, with finasteride slowing hair loss but no noticeable regrowth from minoxidil. They are considering switching to oral minoxidil and dutasteride for better results.

Finasteride's potential side effects, especially sexual dysfunction, are discussed, with emphasis on hormonal balance between testosterone and estradiol. Users share experiences with finasteride, minoxidil, and dutasteride, highlighting the variability in side effects and the influence of mindset and lifestyle.

Swelling after a hair transplant is normal and can be reduced with ice packs, head elevation, and possibly corticosteroids. The user had a no-shave FUE procedure and is using oral finasteride and minoxidil.

The user's experience taking Pyrilutamide, a drug for hair loss treatment, and their use of it in combination with other treatments such as Minoxidil, Finasteride and RU58841. They have experienced positive results so far with no major side effects.

A potential update on the progress of pyrilutamide, a hair loss treatment; and if Kintor should stop their trials.

The effects of smoking cigarettes on DHT levels and its potential effect on hair loss, with some people sharing experiences in relation to their own hair loss. Various treatments for reducing or reversing hair loss were discussed, such as quitting smoking, minoxidil, finasteride and RU58841.

A 57-year-old man with severe hair loss since age 14 tried various hair loss treatments over two years, including finasteride, dutasteride, minoxidil, and supplements, with some minor regrowth. He also experimented with topical treatments and microneedling, but results were not cosmetically significant.